NPM1 and acute myeloid leukemia: Here, we report correlation between MRD levels and patient outcome, using sensitive cDNA – based RQ-PCR assays of two molecular MRD markers, WT1 overexpression and NPM1 mutations in a homogeneous population of AML patients aged 50 to 70 years treated in the multicentric randomized ALFA-0701 trial, which tested the addition of GO to conventional chemotherapy.